Holen Sie sich die Stockscreener-App
7.28
7.02%
-0.55
Handel nachbörslich:
7.30
0.02
+0.27%
Schlusskurs vom Vortag:
$7.83
Offen:
$8
24-Stunden-Volumen:
1.18M
Relative Volume:
0.76
Marktkapitalisierung:
$616.35M
Einnahmen:
$20.65M
Nettoeinkommen (Verlust:
$-192.65M
KGV:
-2.8108
EPS:
-2.59
Netto-Cashflow:
$-134.39M
1W Leistung:
-15.15%
1M Leistung:
+10.81%
6M Leistung:
+42.19%
1J Leistung:
-44.55%
1-Tages-Spanne:
$7.02
$8.025
1-Wochen-Bereich:
$7.02
$9.305
52-Wochen-Spanne:
$4.305
$19.34
Verve Therapeutics Inc Stock (VERV) Company Profile
Firmenname
Verve Therapeutics Inc
Sektor
Branche
Telefon
(978) 501-3026
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie VERV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
7.28 | 616.35M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-10-06 | Eingeleitet | Credit Suisse | Neutral |
| 2022-08-25 | Hochstufung | Stifel | Hold → Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-07-12 | Eingeleitet | Guggenheim | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-12 | Eingeleitet | Jefferies | Buy |
| 2021-07-12 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investors Who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class ActionVERV - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Verve Therapeutics, Inc. (VERV) Investigation - ACCESS Newswire
Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading 10.4% HigherShould You Buy? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading Down 4.9%Time to Sell? - MarketBeat
Verve Therapeutics Inc (VERV)’s stock decline to 7.98 per share - US Post News
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.7%Time to Buy? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Shares Gap UpHere's What Happened - MarketBeat
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Buy Rating for Verve Therapeutics: VERVE-102’s Enhanced Safety and Promising Efficacy Boost Investor Confidence - TipRanks
Verve Therapeutics Inc [VERV] stock for 3,130 USD was sold by Dorval Allison - Knox Daily
Perhaps timely catching Verve Therapeutics Inc (VERV) would be a good idea - SETE News
Verve Therapeutics (NASDAQ:VERV) Shares Down 5.7%What's Next? - MarketBeat
Verve Investor Drops Class Suit Over Halted Clinical Trial (1) - Bloomberg Law
France Programmatic Ad Seller Quality Rankings Q4 2024: Outbrain Tops Pixalate’s Web Seller Trust Index; Verve No. 1 on Mobile - GlobeNewswire Inc.
STATE STREET CORP Reduces Stake in Verve Therapeutics Inc - GuruFocus.com
Verve Therapeutics' Market Cap Up US$69m Following Year Of Insider Stock Buying - Simply Wall St
Is Now The Time To Buy Verve Therapeutics Inc (NASDAQ: VERV) Stock? - Stocks Register
Is Verve Therapeutics Inc (VERV) a threat to investors? - US Post News
China Universal Asset Management Co. Ltd. Buys 1,676 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - ETF Daily News
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Awards $1M+ in Equity Incentives to Accelerate Growth Strategy - StockTitan
Nisa Investment Advisors LLC Raises Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading 5.6% HigherHere's Why - MarketBeat
(VERV) Proactive Strategies - Stock Traders Daily
Millennium Management LLC Reduces Stake in Verve Therapeutics Inc - GuruFocus.com
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm - PR Newswire
Verve Therapeutics (NASDAQ:VERV) Trading Down 8.2%What's Next? - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Nisa Investment Advisors LLC - Defense World
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside Verve's Next Move: CEO Kathiresan Takes Center Stage at Elite Biotech Summit - StockTitan
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth - Yahoo Finance
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading Up 6.1%Should You Buy? - MarketBeat
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last? - Yahoo Finance
Brokers Offer Predictions for VERV FY2025 Earnings - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Forecasts VERV FY2025 Earnings - MarketBeat
(VERV) Trading Advice - Stock Traders Daily
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading 8.6% HigherTime to Buy? - MarketBeat
GAMMA Investing LLC Has $34,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Harbor Capital Advisors Inc. Sells 11,980 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Stake Raised by Barclays PLC - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLC - Defense World
Analysts’ Revisions Show Improving Sentiment For Verve Therapeutics Inc (NASDAQ: VERV) - Stocks Register
Finanzdaten der Verve Therapeutics Inc-Aktie (VERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):